Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, has posted its first set of data on the Forest Clinical Trial Registry.
Access to the registry is unrestricted and available at
http://www.forestclinicaltrials.com or through a link from the Company's homepage http://www.frx.com, the company announced here.
The initial data posted includes results from all paediatric and adolescent studies for Forest's antidepressants Lexapro and Celexa, as well as information regarding ongoing clinical studies for Forest products under development.
Ivan Gergel, chief medical officer at Forest, commented: "We fully support the posting of clinical study results to enable unrestricted access to data by physicians, patients, caregivers and other parties which may be beneficial in assessing available treatment options."
Additional clinical trial information will be added to the registry as completed studies are summarized in registry format, as new studies are initiated, and as ongoing studies are completed and summarized. Full data summaries for completed qualifying clinical studies will be summarized and posted to the registry by December 31, 2005, the release said.